secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001645666-25-000009
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences: positive PORTOLA Phase 2a data; steroid-sparing remissions in AIH, cash $132M
--------------------------------------------------------------------------------

- 31% of zetomipzomib patients achieved CR + steroid taper ≤5 mg/day vs 12.5% placebo in ITT (n=24).
- In steroid-dependent subgroup, 36% zetomipzomib CR + taper ≤5 mg/day vs 0% placebo; median response 27.6 weeks.
- No Grade 4/5 AEs; injection site reactions most common; one placebo SAE (variceal bleed), two zetomipzomib SAEs (fever, flu).
- FY2024 net loss $83.7M vs $101.9M in 2023; cash $132.2M at Dec 31, 2024.
- Company plans to discuss with FDA to remove partial clinical hold and design registrational trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000009/0001645666-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000009/kzr-20250325.htm
  HTML page:      https://secwatch.observer/filing/0001645666-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer